BioSpace2d
Hemogenyx Pharmaceuticals PLC Announces Opening of First Clinical Site
LONDON, UK / ACCESSWIRE / December 30, 2024 / Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the “Company”)(LSE:HEMO) is pleased to announce the opening of the first clinical site for ...
BioSpace2d
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT ...
BioSpace3d
New Paper Calls for More Diversity and Inclusivity in Neuroscientific Research
MANHASSET, N.Y.--(BUSINESS WIRE)--For years, The Feinstein Institutes for Medical Research has been calling attention to the historical lack of diversity and inclusion in medical and scientific ...
BioSpace3d
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc.
BioSpace3d
CEL-SCI Announces Proposed Public Offering of Common Stock
VIENNA, Va.--(BUSINESS WIRE)--$CVM--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company ...
BioSpace3d
CEL-SCI Announces Pricing of $5 Million Public Offering
VIENNA, Va.--(BUSINESS WIRE)--$CVM--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today ...
BioSpace3d
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics ...
BioSpace5d
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Reflects a 1-for-25 reverse stock split effective November 25, 2024.
BioSpace6d
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers ...
BioSpace6d
Matwings Technology Raised Series A Funding of Tens of Millions USD to Redefine Protein Design
SHANGHAI, Dec. 25, 2024 /PRNewswire/ -- Recently, Shanghai Matwings Technology Co., Ltd. (‘Matwings’), a global leader in AI-driven protein design, announced the successful completion of Series A ...
BioSpace5d
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to ...
BioSpace5d
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
BETHESDA, Md., Dec. 26, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor ...